

INDEX

A

2-acetylaminofluorene (AAF), 85, 86, 88-91, 94
abiotic, 98, 101-104
acetylaminofluorene, 6
actinomycetes, 6
acute diseases, 187
acute inflammation, 7, 8, 85, 113-115, 118, 120, 121
adaptation, 20, 102, 103, 133, 190, 191, 194, 198, 206
aerosols, 32
Africa, 206
agglomerates, 50
aggression, 188, 196
agitation, 4, 8, 11, 17, 29, 55, 137, 142, 144, 188, 189
agro-homeopathy, 107
allosteric protein, 127
Alternaria brassicicola, 106, 107
alternative, 11, 198, 206-209
ambiguity, 175
amount of information, 169
amphibian, 137, 138, 143, 145
amphibian metamorphosis, 8, 144
anabolism, 127, 192, 193
anger, 159-162, 166
anger with indignation, 157, 159, 174
anthroposophical medicine, 104
antigen, 8
anxiety of conscience, 159
Apgar Score, 211
apoptosis, 14, 129
aqueous solutions, 32, 33, 38, 43, 52, 53, 55, 58, 142
Aristotle, 50
arsenic trioxide, 103
arteries, 118, 119
artifacts, 5, 8, 12, 17, 32, 33, 72

Asia, 206
asthenia, 188, 189, 194
ATP, 128
atrabiliar temperament, 193, 198
attractor, 77, 78
autoimmune diseases, 14
autopoiesis, 4, 12, 17
Avogadro, A. 4
Avogadro's number, 4, 106, 130, 133

B

Bacon, Francis, 50
Bacon, Roger, 50
bacteria, 9, 17, 18, 33, 59, 99-101, 132, 209, 210
Balb/c mice, 16
barcode scanner, 138, 142, 144, 145
barley seeds, 100
basal membrane, 6, 92
basic research, 11, 83, 97, 98, 107
Basidiomycetes, 131
basophile degranulation, 5, 131, 132
basophiles, 5, 6, 70
Bastide, Madeleine, 3, 5, 6, 10-18, 20, 21, 32, 33, 132
Bayes, Thomas, 152
Bayes' formula, 153, 163, 178
Bayes' law, 161
Bayes' theorem, 151, 160, 162
Bayesian algorithm, 151
Bayesian statistics, 151, 152
behavior, 9, 10, 15, 16, 18-21, 31, 49, 50, 52, 54-61, 67, 75, 77, 113-123, 129, 140, 192, 196, 197, 199
behavioral disturbs, 9
behavioral patterns, 13, 14, 16
Benin, 211
Benveniste, Jacques, 5

- Bergson, 22
 Bernard, Henri, 191
 bias, 69, 73, 155, 162, 173, 175, 177, 178
 bilharziosis, 209, 210
 biliary ducts, 84
 biliary temperament, 192, 193, 198
 bilirubin, 92
 binomial chance calculation, 160
 bioassays, 99, 102, 105
 biochemical mechanisms, 6
 biodiversity, 207
 biological interaction, 33
 biological meanings, 15
 biological responses, 30-33, 76
 biological specificity, 32
 bioluminescence, 100, 101
 biopathographic diagnosis/biopathographic
 diagnostic, 187, 188, 190
 biophysical basis, 78
 biosemiotics, 13
 biotherapeutic(s), 193, 195, 198, 202
 biotypes, sulfuric, phosphoric, carbonic, 191
 biotypologic diagnosis/biotypologic diagnostic,
 187, 188, 190, 191, 195, 196
 blood brain barrier, 76
 body expression, 11
 Boenninghausen technique, 189
 bold type, 157, 164
 borderline cases, 175
 botanical trials, 97
 bound water, 51, 52
 bovine pox-virus, 10, 11
 bradikinin, 121, 122
 Brazilian Homeopathic Pharmacopoeia, 58,
 114
 bubbles, 37, 43, 44
 bulk, 58, 60
 Burkina, Faso 208
 bursin, 16
 bursine, 6
- C**
 cadmium, 7, 16, 102, 103
 calorimetric properties, 30
 CAM, 206-209
 Canada, 206
 canonical discriminant analysis (CDA), 152,
 156-158, 167, 168, 170-172, 180
 capacitance, 58
 capacitor, 56, 59, 60
 carbonic biotype, 195
 carbonism, 191, 192, 195, 197, 198
 carcinogen toxicity, 84
 carrageenan, 7, 113-122
 carrier, 15, 16, 20, 21, 32, 138
 Cartesianism, 13
 catabolism, 127
 cattle, 107, 192
 causality, 4, 11, 160, 176, 187
 Cavendish, Henry, 50
 cavitations, 43, 44
 CD 203c, 5
 cell organization, 7, 11, 17
 cell phones, 8
 cellular cycle, 83
 cellular matrix interactions, 14
 cellular system, 5
 centesimal dilution, 8, 55
 Central America, 107
 central nervous system, 9, 84
 chance, 106, 151, 153, 154, 160, 162, 163,
 166, 180
 chemical carcinogens, 84
 chemical composition, 42, 50
 chickens, 6
 China, 197, 206-208
 cholera, 197, 208, 211
 chronic diseases, 187
 circadian sleep cycle, 77
 circannual rhythm, 17
 circumstantial medicines, 189
 Clark's approach, 76
 classical science, 18
 clathrates, 31
 cli-Fi-Col, 154, 155
 clinic aggravations, 189
 clinical diagnosis, 187, 188, 196, 197
 clinical file, 154, 155
 clinical history, 186-188, 196
 clinical picture, 187, 188, 194-196, 198, 201
 clinical practice, 9, 15, 42, 120, 154, 185, 191
 clinical protocol, 185-202
 cluster dynamics, 30
 clusters, 33, 44, 50-53, 55, 56, 60
 cohort study, 154, 156, 172
 Colombia, 211
 Committee for Methods and Validation
 (CMV), 154, 155
 communication, 13, 14, 16, 18, 21, 8-0, 95, 185
 comparable scale, 155
 complementary, 29, 98, 206, 209
 complex, 5, 12, 14, 16, 49, 56, 57, 69, 80, 92,
 127, 131, 164, 166, 175, 194, 195
 complexity, 13, 17, 32, 33, 50, 55, 77
 complexity theory, 98
 components, 56, 169
 conceptual mistake, 31

conductivity meter, 38, 40
 confirmation bias, 162, 177
 connective tissue, 92, 113-123
 consciousness, 20, 21
 consensus procedures, 154, 172
 constitutional medicines, 191, 192
 constructive interference, 79
 consultations, 158, 178, 179, 188
 consumer health, 107
 contaminants, 32, 42
 context, 5, 6, 11, 13-17, 21, 70, 173, 185, 189
 control group, 8, 9, 15, 16, 70, 71, 97, 143, 144, 178
 co-occurrence, 175
 correlation coefficient, 42
 correlation matrices, 156-158, 166-168, 179
 correlations, 30, 31, 38-40, 42, 44, 70, 156-158, 168, 179, 201
 cress, 103
 crystal, 53
 curative action, 175, 176
 curative potential, 175
 cut-off values, 162, 165-167, 174
 cybernetic regulation, 14, 21
 cyclic or cascade reactions, 127
 cyclines, 83
 cyclones, 83
 cyproheptadine, 7
 cytokines, 14, 83, 84, 122
 cytotoxic agents, 7

D

D_2O , 43, 54, 55
 damped oscillator model, 80
 data collection, 154, 155
 databank, 154, 155
 decision algorithm, 153
 decision process, 153, 154
 deeper organizational, 104
 default value, 179
 degranulated, 5, 116-122
 degranulation, 5, 7, 122, 131, 132
 delta band, 70-77
 Democratic People's Republic of Korea, 208
 Democratic Republic of the Congo, 208
 density, 32, 50, 70, 72-78, 99, 142, 158, 211
 density fluctuation, 32
 Descartes, Rene, 13, 50
 deuterium oxide, 31, *see also* D_2O
 dexamethasone, 6, 8, 16, 85, 86, 88, 90, 91, 94, 95, 114, 117-123, 131
 dexamethasone exerts, 85
 dextrane, 7

diabetes mellitus, 208
 diagnosis of temperament, 187, 188, 192, 196
 diagnosis populations, 151
 diagnostic test, 152
 diarrhea from anticipation, 156
 diasthetic incompatibility, 190
 diasthetic diagnosis, 187, 193
 diathetical chronic illness, 190
 diathetical diseases, 188
 diathesis, 188-190, 193-196, 198, 209, 210
 dielectric constant, 50-57
 diethylnitrosamine, 85, 89, 90
 differential diagnosis, 167, 180
 differentially diagnostic, 170
 diffusion layer, 58
 dinoflagellates, 100, 101
 dipole moment, 50, 55, 56
 discriminant analysis, 157, 172, 179, 180
 discriminant function, 167, 170-172
 dissipative structures, 31
 dissolved gasses, 32
 distilled water, 59, 140, 142
 DNA synthesis, 83
 DNA-viruses, 11
 doctrine, 3, 4
 dose, 7, 8, 54, 55, 67-72, 74-76, 78-80, 85, 86, 88, 98, 104, 107, 127, 130-133, 137, 142
 dose-effect, 8, 68
 dose-response, 67-70, 76, 79, 80
 down-regulation, 10
 drainage, 116, 189
 drainers, 189
 drug proving, 138
 duality, 13, 133
 duckweed, 99, 100
 dwarf peas, 99, 100
 dynamic effects, 20, 39
 dynamic organization, 19
 dynamical effect, 21, 31, 44
 dynamical orientational complexity, 55
 dynamic-clinical diagnosis, 187
 dynamization, 4, 29, 31, 32, 37, 42, 132
 dynamized systems, 4, 8, 29, 45

E

Earth, 49, 50, 205, 211
 ECG, 69
 edema, 7, 8, 113-116, 118-122, 194, 197, 210
 EEG, 69, 70, 77-79
 electrical conductivity, 38-40, 43, 44, 52, 56

- electrical current, 78
 electrical impedance, 56
 electrical properties, 30
 electrocardiogram, 69
 electrochemical behavior, 57
 electrochemistry, 56
 electrode, 44, 57, 58, 70-72
 electroencephalogram, 69
 electromagnetic energy, 8, 143
 electromagnetic fields, 16, 31, 32, 79, 137, 138, 140-145
 electromagnetic nature, 32, 76
 electromagnetic radiations, 8
 electromagnetic signals, 77
 electron microscopy, 129
 electronic flow, 128
 electrophoretic tests, 129
 ELF EMF, 79
 emunctories blocking, 189, 194
 Endler, P.C., 7, 31, 99, 100, 131, 132, 137-140, 143, 145, 146
 energy, 8, 31, 37, 44, 52-54, 60, 127-130, 143, 188
 entangled states, 31, 33
 environment, 4, 12, 17-20, 50, 69, 98, 106, 107, 114, 127, 129, 133, 138, 185, 191, 194, 209, 210
 eosin, 93, 115, 116
 epidermal growth factor (EGF), 84
 epigenetics oscillations, 80
 epistemological criterion, 186
 equipfinality, 78
 equivalent circuit, 56, 57, 59, 60
Ertlichia, 188
 ethanol, 32, 42, 99, 102, 106, 142
 ethical problems, 97
 eukaryotes, 98
 Europe, 206
ex vivo, 8
 exothermic oxidation, 128
 exotic characteristics, 49
 experimental artifacts, 32, 33
 experimental data, 4, 6, 12, 17, 21, 39, 41, 42, 44, 60, 61, 67, 76, 80
 experimental design, 5, 15, 16, 98, 103, 114, 116, 140
 experimental illustrations, 6, 17
 experimental models, 5-8, 10, 12, 17, 84, 85, 120, 121
 extremely diluted solutions, 44, 50, 58
- F**
- family history, 190, 196
 Faraday insulation, 71, 78
 Fast Fourier Transform (FFT)
 algorithm, 73
 fear of death, 156, 163, 165, 168, 170, 171, 174, 178, 180, 210
 fear of the dark, 167
 fever, 18, 188, 195, 206
 feverfew, 102, 103
 Fibonacci spiral, 130
 fibronectin, 14
 fluorism, 191
 flux calorimetry, 44
 footprints, 14
 Fos, 83
 fractal, 78
 fractal concept, 78
 free radicals, 128
 free water, 51, 52
 freezing point, 50
 frequency, 56-61, 68, 71, 73, 79, 106, 143, 168, 189, 198-201
 frogs, 137, 138
 frond, 99, 100
 fungal infections, 104
 fungal pathogens, 98
 fungi, 59, 98-101, 105, 106, 129-131
- G**
- galvanic cell electrode potential, 44
 γ -ray, 54, 55
 GAP junctions, 95
 gasification, 37, 43
 gene expressions, 14
 general organization, 12
 generality, 175
 Germany, 206
 Ghana, 206, 208, 211
 GHHOS scale, 156, 157, 167, 176
 glasses type I, 41
 glasses type III, 38, 40, 42
 global attractor, 78
 globality, 9, 11-13, 17, 159, 210
 glucocorticoids, 122, 194
 glucose, 128, 129
 glycogen, 90, 92, 94, 95
 glycolysis, 129
 gold standard, 156, 172, 175-177
 Gosner's stage, 139
 grinding teeth, 156, 165, 170, 173
 grooming, 9
 Groupe International de Recherche sur l'Infinitésimal (GIRI), 5, 10, 118

H

Hahnemann, Samuel, 3, 29, 37, 79, 80, 152, 153
 Hahnemann's disease classification, 187
 Hahnemannian Centesimal Method, 38, 58, 86, 95
 handmade, 37-48
 heavy metals, 98
 helenalin, 113, 122
 Helmholtz layer, 58
 hematoxylin, 92, 93, 115, 116
 hepatectomy, 6, 83, 85, 87-91, 94
 hepatic proliferation, 6, 85, 94
 hepatic regeneration, 6, 16, 83-85, 87, 88
 hepatocarcinogenesis, 16, 84, 85, 88, 95
 hepatocellular carcinoma, 83
 hepatocyte regeneration, 84
 hepatocytes, 6, 83-85, 88, 90, 91, 95
 herbal medicines, 206-208
 herpes lips, 154, 156, 157, 162, 163, 165, 166, 168, 170, 173-175, 178, 179
 herpes virus, 10, 11
 high dilutions, 4, 18, 21, 29, 31, 49-61, 71, 79, 85, 90, 95, 97, 132
 high dilutions mechanisms of action, 97
 Hill models, 67
 histamine, 5-9, 67, 69-76, 80, 114, 121, 131, 132
 histochemical analysis, 85, 94
 histochemical characterization, 90
 HIV/AIDS, 206, 208
 Hoffmeyer, J., 13
 holistic approach, 98
 homeopathic algorithm, 178
 homeopathic diagnosis, 153
 homeopathic pharmacotechnics, 4, 7, 8
 homeopathic phenomenon, 29-33, 44, 45, 186
 homeopathic prescription, 151, 187
 homeopathic symptoms, 151-181
 homeopathic ultra-dilutions, 13
 Homeopaths Without Borders (HWB), 205, 208, 211
 homeostasis, 14, 69, 70, 77, 78, 133
 homeostatic, 69, 70, 77, 194
 hormesis, 33, 127-134
 hormetic, 133
 hormones, 13, 14, 99, 100, 137, 192, 193
 host response, 70
 humoral immune, 8
 humoral immune reaction, 6, 8
 hydrogen bond, 31, 32, 50-52, 54, 55, 58, 128
 hyperstimulation, 138, 140, 143

hypothesis, 12, 13, 15, 16, 21, 22, 29-32, 38, 39, 43, 53, 54, 60, 80, 95, 98, 100, 122, 138, 178

I

idiosyncratic, 19
 IL3, 16
 image analysis, 92, 118
 image of object, 21
 image of patient and illness, 187
 immunoglobulin, 8
 immunoglobulin A (IgA), 194, 195
 immunoglobulin E (IgE), 5, 194
 immunoglobulin G (IgG), 5, 8, 195
 immunoglobulin M (IgM), 8, 195
 immunological studies, 8
 immunosuppression, 16
 impedance, 56-61
 impedance analysis, 56-58, 61
 impedance diagram, 57
 impedance spectroscopy, 56-58, 60
in vitro studies, 7
 incidence, 95, 178, 179
 independent entities, 166
 indication for the medicine, 157, 164, 165, 173
 indignation, 157, 159, 166, 174
 individuality, 14, 15, 20
 individualization, 15
 inflammatory cells, 8, 115, 116
 inflammatory mediators, 5, 7
 inflammatory process, 6, 113, 120, 121, 189
 information, 12-18, 20, 21, 30-33, 38, 44, 51, 56, 60, 61, 76, 78, 80, 85, 103, 104, 122, 127, 128, 130, 132, 138, 145, 154, 164, 169, 170, 180, 185, 198
 information carrier, 15
 information exchange, 15, 17
 information matrix, 15
 informational models, 33
 informative event, 19, 20
 informative relationship, 20
 initiators, 6, 84, 85, 88, 89
 interaction between symptoms, 166
 interface effects, 58, 60
 inter-group variance, 158
 interpretative hypothesis, 12, 21
 inter-relatedness of symptoms, 156, 158
 interrelations, 164
 interrelations of symptoms, 172, 179
 intracellular chain-reactions, 13
 intra-group variance, 158
 ionic contaminants, 32
 irritability, 160, 188, 197

iso-endopathy, 7, 8, 11, 137
 iso-endopathy principle, 70
 isopathic, 7, 15, 95, 102, 104, 106, 107, 131, 133
 isopathic ultra-dilutions, 13
 isopathy, 11, 15, 16, 33, 86, 90, 107, 133
 isotherapeutic, 7, 15, 17, 210
 italics type, 157, 165
 itch-behavior, 9, 10
 itching, 188, 197
 Ito cells, 84

J
 journal *Nature*, 5
 Jun, 83

K
 Kent, James T., 18, 176, 188
 Kenya, 208
 keynote, 180
 Krebs cycle, 128, 129
 Kupffer cells, 90, 95

L
 laboratory animals, 9, 70
 laboratory plants, 9
 Lagache, Agnès, 3, 12, 13, 15-18, 32
 laminin, 14, 84
 language, 20, 175
 Latin America, 206
 Les Entretiens Internationaux de Monaco, 5
 leukocytes, 116, 117, 121, 122
 level of communication, 13
 LiCl lithium chloride, 31, 3, 54, 55, 58-61
 life quality, 188, 189, 193
 light lesional stage, 189
 likelihood ratio (LR), 152-169, 172-181
 linear fitting, 40, 41, 43
 linear primary modulation, 13
 liquid water, 50, 52, 53
 liver, 83-85, 87, 88, 90, 94, 95, 189, 195
 living beings, 4, 12-14, 18-20, 69, 70, 77, 79, 80
 living systems, 7, 11, 12, 14-17, 33, 79, 129
 loquacity, 156, 164, 165, 168-170, 173, 175, 177
 low potencies, 43, 103, 104
 LR assessment, 154, 156, 162, 165, 167, 173, 177, 179
 LR project, 154, 173, 178, 179
 luminescence, 32, 53, 54

luminescence methods, 129
 luminometry, 130
 lupus, 16
 lymphatic absorption, 115, 116, 120, 122
 lymphatic vessels, 116, 119, 122
 lymphocytes, 14, 115, 117, 121

M
 Madagascar, 211
 malaria, 206, 208, 210, 221
 Mali, 206, 208
 margin for error, 175
 Masson's trichrome, 90, 91, 93, 94
 mast cell histamine degranulation, 7
 mast cells, 6, 116-122
 materia medica, 15, 29, 151, 160, 162, 171-173, 175, 180
 Materia Medica Validation, 154, 155, 160, 163, 167, 173
 Mathematical, 16, 38, 39, 42, 57, 76, 77, 158
 mathematical analysis, 69, 71, 72
 mathematical models, 9, 12, 67, 79
 Maturana, H.R., 14, 99
 MCH, 14, 99
 meaningful, 12, 15, 19, 20
 mechanical, 4, 19
 mechanical agitation, 55
 mechanical arm, 59
 mechanical machine, 38
 mechanical succession, 37, 38, 43
 mechanism, 4
 mechanism, 3, 4, 6, 7, 9, 12, 31, 37, 44, 51, 55, 68-70, 79, 80, 83, 85, 97, 121, 122, 127, 128, 130, 133, 134, 185, 187, 190, 192, 196
 mechanism of action, 4, 7, 85, 185
 mechanistic, 4, 10, 68
 mechanistic paradigm, 3, 13
 medical diagnosis, 196
 medicine population, 151, 157, 162, 168, 180
 melting point, 50
 memory, 8, 11, 17, 29, 30, 133, 152
 memory of water, 5
 metabolic oscillations, 80
 metabolism, 95, 127-129, 191-195
 metaloproteins, 128
 metamorphosis, 7, 8, 131, 137, 138, 140, 144
 methyl-histamine, 5
 miasma, 193, 209, 210
 micro domains, 51, 52
 microbial trials, 97
 microorganisms, 18, 97-108, 133
 microwave oven, 8, 138, 142, 144, 145

middle ages, 4, 113
 migration, 8, 85, 116, 117, 121, 122, 191
 minimum syndrome of maximum value, 187
 misleading entries, 163, 180
 misleading repertory-entry, 163
 mitochondria, 128, 129
 mobile phone, 138, 142, 144, 145
 modeling, 51, 56, 57, 67
 modified Glick, 90
 modulation, 5, 12, 13, 79, 80, 94, 121, 122
 modulator, 5-8, 11, 17, 70, 120
 molecular communication, 14
 molecular interactions, 52
 molecules, 5, 7, 9, 12-14, 30-32, 42-44, 49-56, 92, 106, 128
 molecule-receptor system, 9
 monisms, 13
 monocytes, 115, 117
 monomer, 56
 Montpellier, 5
 morbid process, 188, 189
 morphometric analysis, 87, 89
 morphometrical characterization, 90
 Mpemba, Erasto, 50
 multi-centre trial, 100, 108
 multicentric study, 5, 7
 multidisciplinary, 33
 multivariate analysis, 156, 158, 167, 172, 179
 Myc, 83

N

NaCl (sodium chloride), 31, 43, 54, 55, 100, 102, 103
 nanobubbles, 31
 nano-pharmacology, 134
 natural sciences, 13, 67
 nematodes, 98, 105, 106
 neonatology, 211
 neuron, 7, 78
 NFk(kappa)B, 83, 85
 nidogen, 14
 Nigeria, 206, 208
 NMR, 32
 no linearly network, 12
 Nocardia, 129-131
 noise, 32, 79, 80, 104
 non linear system, 58, 79, 80
 non local effects, 31
 non-conventional medicine (NCM), 205-211
 non-linearity, 8, 9, 11, 12, 17, 67-81
 non-molecular information, 12, 14, 16
 non-monotonic dependence, 53, 54
 non-REM sleep, 70

normality, 10, 11, 17, 73
 North America, 206
 noxae, 104
 NREM sleep, 77
 nuclear transcription, 83
 Nyquist diagram, 56
 Nyquist theorem, 71

O

occurrence, 58, 151, 152, 154, 162, 173, 175, 178, 188, 191, 193-195
 oncogenesis, 84
 open cohort studies, 154, 156, 172
 organic agriculture, 107
 organizational structure, 49, 51, 53
 Organon, 3, 29
 organotherapies, 189, 198
 oscillating, 80
 oscillations, 16, 17, 76, 80, 132, 133, 145, 198
 oscillator, 76, 80, 129
 oscillatory, 5, 8, 68, 75, 76, 133
 oscillatory pattern, 80
 oscillatory potency-effect curve, 5, 8
 oval cells, 6, 87, 95
 oxydoreductases, 128, 129, 131, 132
 oxygenases, 128, 129

P

p53, 83
 painful feeling, 188
 paradigm of the sign, 13
 pathogenetic images, 187, 196, 198
 pathogenetic symptom, 159, 160
 pathological conditions, 6, 13, 100-102, 106, 122
 pathological history, 188, 190, 196
 pathological patterns, 9
 pathophysiological moment, 188, 189
 pattern recognition, 158, 164
 patterns of symptoms, 179
 peculiar symptoms, 152, 153, 162, 181
 periodic acid-Schiff (PAS), 92, 116, 118
 peroxidase, 120-132
 personal traits, 151
 Peru, 208, 211
 pharmacogenetics, 151
 pharmacology, 6, 9, 12
 Pharmacopoeia, 38, 42, 98
 phenolic, 129, 130
 phenomenological approach, 12
 phenomenological models, 33
 phenotype, 6, 16, 89, 90

- phosphoric biotype, 188, 195
 phosphorism, 191, 192
 phosphorus, 15, 100, 106, 153, 168, 188, 191, 195, 197, 200, 210
 physical chemistry properties, 38, 43
 physical properties, 31, 33, 50, 52
 physical-chemical models, 29-31
 physical-chemical variations, 30
 physical-chemistry parameters, 69
 phytopathological models, 98, 104
Phytophthora infestans, 106, 107
 piece of information, 14, 15, 20, 21
 Pillars, 4
 Pivot tables, 157
 placebo, 9, 97
 plain type, 157
 plant- and microorganism-based experimentation, 97
 plant hormones, 99, 100
 plant immunity, 133
 plants, 9, 32, 97-108, 127, 131-133, 207, 209
 plasticity, 192, 193
 pleural cavity, 116
 PMN (polymorphonuclear) cells, 115, 117, 121, 122
 Poisson regression, 67
 polytraumatic injuries, 113
 positive gradient, 155
 possessiveness, 188
 posterior odds, 153
 post-surgical edema, 121
 potency-effect curve, 5, 8, 9
 potentization, 4, 33, 37, 38, 43, 44, 103, 130, 131
 Potentization *see also* dynamization
 potentized (or dynamized) systems, 4, 8, 12, 29-33
 potentized gamma radiation, 103
 power laws, 77
 practice experience, 172, 180
 preclinical studies, 97
 preneoplastic nodes, 6, 16
 pre-neoplastic lesions (PNLs), 89-91, 94, 95
 prescriptions, 151, 154, 157
 prevalence, 77, 151-157, 160-163, 165, 168, 173, 174, 178, 179, 181, 198
 previous conditions, 7, 11, 12, 17
 Prigogine, I., 31
 principal component analysis (PCA), 156-158, 167-169, 179
 promoters, 84, 89
 prospective assessment, 152, 156, 162, 173, 177
 prospective investigation, 161, 162, 173
 prospective LR research, 160, 172, 174, 176, 178, 180
 prostaglandins, 7, 114, 121, 122
 proto-oncogenes, 6
 proving, 9, 32, 38, 122, 138, 155, 159, 201
 Prussian blue, 90, 93-95
 psora, 194, 197, 198
 psychological disturbs, 9
 public health, 205-211
 pyruvic acid, 128
- Q**
- qualitative, 80, 90, 175
 quality of life, 9
 quantitative, 76, 90, 175
 quantum nature, 33
 questionnaire, 180
 quiet wakefulness, 77
- R**
- RADAR®, 154, 157
 RADAR-Synthesis®, 157
 radiation, 8, 52, 103, 133, 145
 Raman, 32
Rana catesbeiana, 7
Rana temporaria, 7, 137, 139, 140
 random disturbance, 69
 rare symptoms, 153
 recall bias, 162, 178
 receiver, 15, 16, 20
 recursive, 12, 67
 red light scan, 138, 142, 144, 145
 reference “gold” standard, 172, 175-177
 refraction, 52
 regenerative hepatic process, 83
 relative growth rate, 75, 76
 repertorisations, 152, 154, 166, 175, 196
 repertory, 151, 152, 154, 155, 157, 158, 160, 162-167, 172-175, 177, 179-181, 197
 reportorial images, 196, 197
 reproducibility, 60, 97, 103, 104, 138, 173
 Republic of Korea, 208
 resistance, 41, 42, 56, 58, 60, 70, 84, 105, 106
 resistant hepatocyte model, 88, 91
 resonance, 20, 21, 79, 133
 resonant behaviors, 60
 respiratory chain system, 129
 retrospective analysis, 152, 161, 181
 retrospective assessment, 173
 retrospective investigation, 173, 178
 retrospective study, 154, 155, 174
 Robinson Crusoe, 14

rubrics, 151, 152, 155, 157, 159, 160, 162-164, 166, 173-175, 177, 181, 197

S

Saccharomyces cerevisiae, 101
 satellite pictures, 158
 scale, 55, 77, 78, 155, 156, 176, 201
Schizosaccharomyces pombe, 101
 scree-plot, 169
 self response, 79, 80
 Self-Organized Critically (SOC), 77, 78
 self-similarity, 77
 semantic, 9, 13
 semantic objects, 12, 13, 15, 17
 semantically similar, 155, 173
 semantics, 166, 173
 semiosis, 4
 semiotic notions, 12
 semiotics, 13, 29
 sensibility, 31, 32, 210
 sensitive systems, 12, 13, 104
 sensitivity to injustice, 154, 156, 157, 161, 164, 166, 168, 170, 171, 173, 177
 serotonin, 121, 122
 severe lesional stages, 189
 side effects, 9
 signals, 20, 32, 54, 58, 69, 71, 77, 79, 80, 127, 145, 188, 189
 signal-to-noise ratio (SNR), 32, 79
 silica, 31, 32, 42
 silver nitrate, 100
 silver staining, 118
 similarities, 8-11, 15, 16, 21, 29, 30, 33, 77, 79, 165, 170, 173, 187
 similarity law, 160, 209, 210
 similarity models, 8
 similia principle,
 similitude, 33, 122
 sinusoidal curve, 132
 sleep, 69, 70, 72, 76, 77, 80, 156, 160, 164, 165, 173
 sleep pattern, 70
 sleep-wake, 70
 slow water dynamics, 30
 slow-wave activity, 70
 soft science, 13
 software requirements, 178
 solvent, 15, 16, 30, 32, 44, 55, 71, 76, 142, 145
 solvent structure, 32, 45
 Sorites paradox, 175
 Sorites vagueness, 175
 South America, 107, 111
 specific heath, 50

specificity, 5, 7, 11, 15, 17, 18, 20, 32, 61, 92, 131, 191
 spectral density, 70, 72-74
 spectrophotometry, 115, 130
 spectroscopy, 56, 58, 60, 129
 SPSS, 158
 stable cells, 83
 stationary state, 77
 statistical knowledge, 180
 statistical uncertainty, 173, 174
 statistical variance, 152
 stem cells, 6, 84
 stochastic, 69, 173
 stochastic resonance, 79
 stressed organisms, 104
 structural closure, 17
 structural models, 45, 51
 structure, 17-21, 30-33, 49-54, 60, 67, 69, 79, 84, 87, 90, 93, 97, 98, 100, 118, 128, 129, 191, 198
 succession, 11
 sulphuric constitution, 191
 sunflower, 103
 surface tension, 50
 sustainability, 207
 sustainable agriculture, 98, 107
 sycosis, 194, 195, 197, 198, 210
 symbolic information, 13
 symptoms, 4, 7, 9-11, 17, 19, 20, 29-31, 80, 104, 105, 107, 122, 151-181, 185-188, 196, 197, 201, 202, 209, 210
 synergic action, 13
 syphilinism, 194, 195, 198
 system sensitivity, 104

T

TCR, 14
 temperamental diagnosis, 188
 tension, 50, 56, 58
 theorem, 71, 152, 160, 162
 theoretical explanations, 30, 145
 theoretical models, 31, 33, 97
 Theory of (the) Corporeal Signifiers, 3-22
 thermoluminescence, 31, 43, 54, 55
 thymulin, 16, 21
 thymus, 14
 thyroxin, 7, 8, 131, 137, 138, 140-145
 T-lymphocytes, 14
 TM/CAM, 207, 208
 tobacco, 98, 105, 106
 tobacco mosaic virus (TMV), 105, 106
 Togo, 211
 toluidine blue, 116-118

tonicity, 192-194
 totality, 9, 11, 17-19, 187, 196, 209
 toxicology, 7, 187
 traditional medicine, 206-208
 transforming growth factor (TGF), 84
 triggering, 5, 8, 127
 tuberculinism, 194, 195, 210
 tuberculosis, 210
 tumoral lineage, 7
 turbulence, 43, 44
 type I allergic reaction, 194
 type I hypersensitiveness, 9
 type II hypersensitivity, 195
 type IV allergic manifestations, 195
 type of shaking, 131

U

Uganda, 208
 ultra highly diluted substances, 97
 ultra-diluted dexamethasone, 6, 8
 ultra-dilutions, 3-22, 67-81
 ultra-high dilutions, 43, 50, 52-56, 58, 60, 83-95, 98
 ultra-low dose, 68, 72-76, 79, 80
 United Kingdom, 206
 United States, 38, 206, 207
 unsuccessful medium, 100, 101

V

Vaccinia, 10
Vaccinotoxinum, 11
 vague symptoms, 154, 162, 166
 vagueness, 157, 162, 172, 175, 177
 validation criteria, 29, 30
 Van der Waals interactions, 52
varicela, 10
 vascular permeability, 114, 116, 121, 122
 vasodilatation, 9
 very low doses, 43, 127-133
 veterinary homeopathy, 186
 veterinary medical specialty, 186
 vibration modes, 51

Vietnam, 208
 vincristine, 43
 viral pathogens, 98
 virology, 10
 viruses, 10, 11, 97-108, 209
 viscosity, 50
 vital functions, 104
 vitalism, 4, 21
 voltage fields, 78
 vortex, 8, 37, 43, 44

W

water, 5, 7, 15, 16, 29, 30, 32, 38-45, 48-61, 71, 86, 92-94, 102, 103, 105, 106, 114, 116, 128, 133, 137, 139-145
 water cluster hypothesis, 32
 water dynamics, 30, 32
 water infrared absorption spectra, 51
 water memory, 29, 30, 133
 wave graph, 132
 wave length, 46, 53, 132
 wave shape, 131, 133
 waves, 53, 54, 70, 77, 132, 133, 145
 weakening of quantum theory, 31
 weakness, 188, 189
 wheat, 98, 102, 103, 105
 wheat seeds, 103
 Winchip® program, 154
 World Health Organization (WHO), 206-208

X

x-ray, 55, 138, 142, 144, 145, 201

Y

yeasts, 98, 102

Z

Zimbabwe, 208
zona, 10, 11